NCT07652658
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Recruiting
PHASE2Ages 40+InterventionalTreatmentAstraZeneca
~359 participants
Updated 2026-06-25 on ClinicalTrials.gov
What's tested:Placebo for AZD8965AZD8965 low doseAZD8965 medium doseAZD8965 high dose
At a glance
Recruiting sites
4 of 190 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24
Measured over at Week 24
Conditions
Where it's being run
190 sites across 46 statesGermany17
China16
Japan15
Mexico9
France8
Italy8
Taiwan8
Argentina6
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24at Week 24
To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24